WIXLIB

Program12B Layout 1 3/5/2020 10:39 AM Page 5HELEN DILLER FAMILYCOMPREHENSIVE CANCER CENTERIn 1948, the University of California at San Francisco (UCSF)established the Cancer Research Institute, a precursor to consolidationof its cancer activities in more recent decades. NCI designation asa comprehensive cancer center came in 1999 and the Center wasrenamed the UCSF Helen Diller Family Comprehensive CancerCenter in 2007.The UCSF Helen Diller Family Comprehensive Cancer Center wasthe first center in the Bay Area to receive the prestigious designationof “comprehensive” from the National Cancer Institute. The HelenDiller Family Comprehensive Cancer Center treats all forms of cancer.With new facilities, expanded programs and innovative research, it helps cancer patients live longerand fuller lives. UCSF Helen Diller Family Comprehensive Cancer Center is an NCI-designated CancerCenter, affiliated with the UCSF School of Medicine and the UCSF Medical Center. It is one of 69cancer research institutions in the United States supported by the National Cancer Institute, and oneof three in Northern California. The Helen Diller Family Comprehensive Cancer Center providesexceptional patient care at: UCSF Medical Center at Mount Zion, UCSF Medical Center at Mission Bay,UCSF Medical Center at Parnassus, Zuckerberg San Francisco General Hospital, and the San FranciscoVeterans Affairs Medical Center.The UCSF Helen Diller Family Comprehensive Cancer Center combines basic science, clinical research,epidemiology/cancer control and patient care from throughout the University of California, SanFrancisco system. UCSF’s long tradition of excellence in cancer research includes the Nobel Prizewinning work of J. Michael Bishop and Harold Varmus, who discovered cancer-causing oncogenes.Their work opened new doors for exploring genetic abnormalities that cause cancer, and formed thebasis for some of the most important cancer research happening today.Basic Scientific ResearchFrom understanding normal cellular processes to discovering the underlying molecular and geneticcauses of cancer when these processes go awry, UCSF researchers are committed to moving scientificinsights forward and pursuing their relevance for clinical oncology and cancer prevention.Clinical ResearchClinical scientists explore how a greater understanding of fundamental biological events can betransformed into clinical tools. New forms of cancer treatment, as well as innovations in diagnosis andprognosis, undergo rigorous evaluation for safety and efficacy. This translates into improved patientoutcomes and hope for the future.Patient CareThe Helen Diller Family ComprehensiveCancer Center provides exceptionalpatient care at five San Franciscomedical centers: UCSF Medical Centerat Mount Zion, UCSF Medical Center atMission Bay, UCSF Medical Center atParnassus, Zuckerberg San FranciscoGeneral Hospital and Trauma Center,and the San Francisco Veterans AffairsMedical Center.4

Program12B Layout 1 3/5/2020 10:39 AM Page 6CALIFORNIAProstateCancerCPCC/UCSF PATIENT CONFERENCEON PROSTATE CANCERJune 8, 2019COAL I T IONAGENDASession NameTimeRegistration / Breakfast7:00 - 8:00I. THE BASICS: Session Chair, Eric Small, MD1. Introduction and welcome8:00 - 8:15Merel Nissenberg, Esq, Stan Rosenfeld,Eric Small, MD2. Prostate Cancer 101:The basics you need to know8:15 - 8:35Peter Carroll, MD, MPH3. Prostate Cancer Genetics 1018:35 - 8:55Felix Feng, MD4. Basics of Prostate CancerImmunology andImmunotherapeutics8:55 - 9:15David Oh, MD5. Demystifying Clinical Trials:What are they, and whatshould you think aboutwhen considering a trial?9:15 - 9:35Rahul Aggarwal, MD6. The ABCs ofAndrogen Deprivation Therapy9:35 - 9:55Eric Small, MDMORNING BREAK9:55 - 10:15II. TREATMENT OF NON-METASTATIC DISEASE BASED ON RISK ASSESSEMENT:Session Chair, Peter Carroll, MD7. Disease Location and RiskAssessment: the scientifictools available to helpwith clinical decision making10:15 - 10:45Peter Carroll, MD, MPHMatt Cooperberg, MD, MPHFelix Feng, MDTom Hope, MD8. Low Risk Localized PCa:Genomic Tests, FocalTreatment andActive Surveillance10:45 - 11:15Peter Carroll, MD, MPHLeonard Marks, MD9. Intermediate and High-riskDisease and multimodaltherapy11:15 - 11:45Matt Cooperberg, MD, MPHMack Roach, MDEric Small, MDJames Yu, MD5

Program12B Layout 1 3/5/2020 10:39 AM Page 7AGENDA (continued)Session NameTimeSPECIAL LECTURE:11:45 -12:30“Working with Your Primary Care Physician”LUNCHMeet the Professors12:30 -1:30Joseph Scherger, MD, MPHEric Small, MDPeter Carroll, MD, MPHFelix Feng, MDOthersIII. A SYSTEMATIC APPROACH TO SYSTEMIC THERAPY: Session Chair, Rahul Aggarwal, MD10. The optimal treatment ofbone metastases1:30 -1:45TBD11. New and DevelopingTreatment Approaches forpatients with non-localizedprostate cancer1:45 -2:15Eric Small, MDRahul Aggarwal, MD12. The role of Diet and Exercisein addressing Prostate Cancer2:15 -2:30June Chan, Sc.DAFTERNOON BREAK2:30 -2:50IV. FROM THE PATIENT'S PERSPECTIVE: Session Chair, Stan Rosenfeld13. Managing the side effectsof prostate cancer andits treatment2:50 -3:20Alan Shindel, MDMike Rabow, MDNannette Perez, NP14. Access to care andoptimizing care receivedfrom Community Physicians3:20 -3:50Merel Nissenberg, EsqTom Kirk, Brad Ekstrand, MDDavid Lowther, MD15. Practical tips for theconsumer including howto approach decision-making3:50 - 4:20Tia WeinbergEric Small, MD and Stan Rosenfeldwill interview three patients:Joe Ferrara, Richard Ridington andWalt TraskCLOSING AND WRAP-UP4:20 – 5:006

Program12B Layout 1 3/5/2020 10:39 AM Page 8CPCC/UCSF PROSTATE CANCER CONFERENCEFACULTY BIOSProstate Award and the SUO Medal from the AUA and SUO,respectively. In 2014, he was also awarded the covetedBarringer Medal from the American Association ofGenitourinary Surgeons. This award recognizes a youngermember who is achieving “distinguished accomplishments.”In 2017, he accepted a position as AAGUS Treasurer. He isalso the Taube Family Distinguished Professor in UrologyDepartment of Urology.Dr. Carroll is committed to reducing the burden ofprostate cancer treatment – physical, psychological, andmonetary. He pioneered and remains a vocal advocate forstandardizing an active surveillance regimen in patientswith low-volume, early stage prostate cancer. Activesurveillance carefully determines which patients can safelypostpone radical treatment while still maintaining anacceptably low risk of cancer progression. At the same time,by improving early prognostic capabilities, Dr. Carroll strivesto identify which men may benefit from more aggressiveearly therapies.RAHUL AGGARWAL, MDDr. Rahul Aggarwal is a specialist in cancersof the genital and urinary organs at theUCSF Helen Diller Family ComprehensiveCancer Center. He also serves as director ofthe UCSF STAND (Supportive Therapy inAndrogen Deprivation) Clinic, which providescomprehensive care to men who arereceiving androgen deprivation therapy, hormone therapyfor prostate cancer.As a member of the Developmental TherapeuticsGenitourinary Cancer Program, Aggarwal enrolls patientswith advanced solid tumor malignancies into early-phaseclinical trials of novel targeted treatments. His researchfocuses on developing hormonal treatment strategies thatreduce the toxicity of androgen deprivation therapy formen with advanced prostate cancer. He is also interested indeveloping new molecular imaging techniques that willhelp predict how advanced solid tumors will respond totreatment.Aggarwal earned his medical degree from theNorthwestern University Feinberg School of Medicine. AtUCSF, he completed an internship and residency in internalmedicine, followed by a clinical fellowship in hematologyand oncology. Aggarwal has also been a research fellow indevelopmental therapeutics at Genentech. He is a memberof the American Society of Clinical Oncology (ASCO) andrecipient of the ASCO/Conquer Cancer Foundation YoungInvestigator Award.JUNE CHAN, Sc.DDr. June Chan earned her AB at HarvardCollege in applied mathematics, followedby a doctorate in science from the HarvardSchool of Public Health. She was a FulbrightScholar in Sweden and completed a postdoctoral fellowship at the Department ofEpidemiology at the Harvard School ofPublic Health. Dr. Chan received a CapCURE (now known asthe Prostate Cancer Foundation) Young Investigator Award;and was awarded the Steven and Christine Burd-SafewayDistinguished Professorship in 2009. Dr. Chan is a memberof the UCSF Prostate Cancer Center.Dr. June M. Chan has broad interests in cancer preventionand public health, in particular what individuals can do tomodify their risk of chronic disease, co-morbidity, anddeath. She has expertise and interests in epidemiology andmedical education; and has conducted research on diabetes,pancreatic, colon, and prostate cancer.Dr. Chan’s current research is focused on understandinghow diet, exercise, hormones, and genetics contribute toprostate cancer incidence, progression, and death. She isparticularly interested in identifying modifiable lifestyle riskfactors for prostate cancer progression, and using thisinformation to help us better understand prostate cancerbiology as well as inform public health guidelines. The goalsof her clinical and translational research studies are toidentify risk-reduction strategies for men with or at highrisk for prostate cancer; evaluate novel molecular markers ofprostate cancer aggressiveness that may improve screening,diagnosis, or prognosis of clinically relevant disease; andimprove cancer survivorship for the millions of men livingwith prostate cancer worldwide.She is PI of the prospective national Diet and LifestyleStudy within the Cancer of the Prostate Strategic UrologicResearch Endeavor (CaPSURE), and a multi-site clinic-basedcohort study examining nutritional and genetic risk factorsfor aggressive prostate cancer. She also collaborates withcolleagues at the Harvard School of Public Health on theHealth Professionals Follow-up Study to examine diet andlifestyle risk factors for prostate cancer progression,metastases, and death.PETER CARROLL, MD, MPHDr. Peter Carroll is a Professor and Chair ofthe UCSF Department of Urology. He receivedhis Medical Degree with Honors fromGeorgetown University School of Medicine,and came to UCSF for his general surgerytraining and urology residency. He completeda fellowship in urologic oncology atMemorial Sloan-Kettering Cancer Center and joined theUCSF Department of Urology in 1986.Dr. Carroll organized the Urologic Oncology Service, oneof the most active multidisciplinary programs at UCSF.In 1996 he assumed the Chair of the UCSF Department ofUrology, consistently ranked as one of the top urologydepartments in the country by U.S. News and World Report.He holds the Ken and Donna Derr-Chevron DistinguishedProfessorship, and he served as surgeon-in-chief of the UCSFComprehensive Cancer Center from 2003 through April2007. In September 20006, Dr. Carroll became the Directorof Strategic Planning and Clinical Services of the UCSF HelenDiller Family Comprehensive Cancer Center and AssociateDean, School of Medicine. In May 2008 he earned his MPHfrom UC Berkeley.Dr. Carroll has authored or co-authored over 500publications. He is now Past President of the AmericanBoard of Urology (2006-2008). He is currently principal orco-investigator on numerous scientific studies. His majorprofessional interests are the study and management ofurologic cancers, innovative methods of urinary tractreconstruction, health services research, health policy andthe impact of cancer detection and treatment on quality oflife.Dr. Carroll was awarded the 2010 Eugene Fuller Triennial(continued on next page)7

Program12B Layout 1 3/5/2020 10:39 AM Page 9FACULTY BIOS (continued)informed decisions about both treatments and managementof short- and long-term treatment sequelae. He is also veryinterested in disparities in prostate cancer access andoutcomes, and in prostate cancer as an internationaldisease. He helped forge a number of inter-continentalcollaborations which are yielding fascinating insights intoprostate cancer’s variation in presentation and outcomearound the world. He has received numerous awards for hisresearch papers and is co-investigator on multiple grants.He won a prestigious Young Investigator Award from theProstate Cancer Foundation, and is a current investigatoron a number of ongoing Federal grants including his firstR01 as principle investigator, awarded in 2016 to studymicroRNAs as candidate prostate cancer biomarkers.MATTHEW COOPERBERG, MD, MPHDr. Matthew Cooperberg received hisundergraduate training from DartmouthCollege, where he earned a degree in Englishwith high honors. He then enrolled in YaleUniversity’s MD, MPH program, concurrentlyearning an MPH with a concentrationin Health Policy from the School ofEpidemiology and Public Health, and a MD from the Schoolof Medicine. He completed his General Surgery and Urologytraining at the University of California, San Francisco, andsubsequently continued at UCSF to complete a fellowshipin Urologic Oncology under the guidance of Peter Carroll,MD, MPH. In 2009, Dr. Cooperberg was recruited to join thefaculty at UCSF and the San Francisco VeteransAffairs Medical Center. Specializing in urologic cancercare, he is part of the multidisciplinary urologic oncologyteam of the UCSF Helen Diller Family ComprehensiveCancer Center, located primarily at the Mission Bay campus.He also maintains privileges at San Francisco GeneralHospital. In 2013, Dr. Cooperberg received the first HelenDiller Family Chair in Urology and a secondary appointmentin the Department of Epidemiology and Biostatistics. In2015 he won the American Urological Association GoldCystoscope Award, given annually to one urologist forcontributions to the field in the first 10 years of practice,and was also named Young Urologist of the Year. He wasnamed professor in 2018.Dr. Cooperberg’s clinical interests include the earlydetection, diagnosis, and management of genitourinarymalignancy, and using minimally invasive techniques totreat benign and malignant diseases. He performs robotic,laparoscopic, endoscopic, and percutaneous surgeries, andis interested in incorporating promising new technologiesinto his practice. He is particularly interested in riskstratifying prostate, renal, and other tumors, and matchingtreatments appropriately to those patients most likely tobenefit, using novel imaging tests and biomarkers togetherwith clinical information. Dr. Cooperberg is a Fellow of theAmerican College of Surgeons, and a member of theAmerican Urological Association (AUA) and the Society forUrologic Oncology. In 2012. Dr. Cooperberg co-wrote aproposal to establish a national urology registry. From thisproposal developed the AUA Quality (AQUA) Registry, anational database tracking practice patterns, quality ofcare, and both clinical and patient-reported outcomes forpatients across the U.S. with prostate cancer and otherurologic conditions. Dr. Cooperberg continues in a seniorleadership role with the project.Drawing on the CaPSURE registry, UCSF’s institutionaldatabases, and other data resources, Dr. Cooperberg haswritten over 295 peer-reviewed scientific articles, and hasbeen invited to present his research findings at manynational and international conferences. His primaryresearch focus is prostate cancer, with particular areas ofinterest including: 1) health services research, documentingongoing trends and regional variation in the use ofdiagnostic, imaging, and therapeutic interventions for menwith all stages of prostate cancer; 2) risk assessment andbiomarker research, developing and validating prognostictools incorporating both standard clinical information andemerging biomarkers; 3) comparative effectivenessresearch, examining evidence regarding the relative benefitsof surgery, radiation, and other treatments in terms ofcancer control, quality of life, and cost; and 4) decisionsupport and survivorship, helping men make better-BRADLEY EKSTRAND, MD, PhDDr. Bradley Ekstrand sees patients atCalifornia Cancer Care, combining a scientist’sperspective on the latest in cancer biologywith a healer’s ability to care for the wholepatient and not just treat the disease. WhileDr. Ekstrand sees a wide variety of patientswith cancer, he has particular interests intreating patients with genitourinary malignancies andlymphomas.Dr. Ekstrand earned his MD as well as a Ph.D. (studyingcancer biology) from Yale University School of Medicine. Hereceived his B.S. in Chemistry from Stanford University,where he earned Phi Beta Kappa honors. Dr. Ekstrandattended Mount Sinai Medical Center in New York for hisInternship and Residency in Internal Medicine. For hisFellowship in Medical Oncology he trained at StanfordUniversity School of Medicine. He has co-authored numerousscientific publications within the field of molecular biologyand medical oncology. He is board certified in both InternalMedicine and Medical Oncology.Dr. Ekstrand has ongoing experience in Phase I, II, III, andIV Clinical Pharmaceutical Trials as a Principal and/or SubInvestigator. He also currently serves on the Board of Directorsfor the Association of Northern California Oncologists.FELIX FENG, MDDr. Felix Feng, MD, received his undergraduate training from Stanford University,where he earned a degree in BiologicalSciences and received a President’s Awardfor Academic Excellence. He then receivedhis MD from Washington University in St.Louis, where he received numerous awardsfor his research and academic achievements. He thencompleted both a postdoctoral research fellowship and hisresidency in radiation oncology at the University of Michigan,and subsequently joined the faculty there. In addition tobeing the Director of the Division of TranslationalGenomics, Dr. Feng also co-led the multidisciplinary clinicfor prostate cancer patients and served as Director of theGenitourinary Cancer Program within the Department ofRadiation Oncology at the University of Michigan. In 2016,Dr. Feng was recruited to join the faculty at UCSF, where hecurrently is an Associate Professor of Radiation Oncology,Urology, and Medicine, and serves as Vice Chair for FacultyDevelopment and Director of Translational Research for theDepartment of Radiation Oncology.Dr. Feng’s clinical interests include the diagnosis andmanagement of genitourinary malignancies. He specializes(continued on next page)8

Program12B Layout 1 3/5/2020 10:39 AM Page 10FACULTY BIOS (continued)at the Cats Restaurant in Los Gatos. He and his wife, Dottie,serve on the steering committee of the SCCPSG.FELIX FENG, MD, (continued)in the treatment of high-risk aggressive prostate cancers aswell as oligometastatic disease. For upfront or post-surgicaltreatment for patients, his therapeutic approaches includeintensity-modulated radiation therapy as well as stereotacticablative radiotherapy, among many others. Dr. Feng isnationally known for his approaches of using molecularbiomarkers to help guide or personalize radiation therapy forpatients. He serves as the leader of the Genitourinary CancerTranslational Research Program for the NRG Clinical TrialsGroup, and is a member of the National Cancer InstituteSteering Committee for Genitourinary Cancers. He has helpedconduct numerous clinical trials, and is the co-principalinvestigator of one of the first biomarker-driven clinical trialsfor patients with metastatic prostate cancer.Dr. Feng is a physician-scientist focused on clinical andtranslational research aimed at improving outcomes forpatients with prostate cancer. His laboratory focuses onidentifying and validating biomarkers associated withtreatment resistance in prostate cancer patients, and overcoming radiation or hormone therapy resistance withtargeted therapy. He has published over 130 peer-reviewedscientific articles, and his major contributions to the medicalfield include: 1) the development of novel molecularsubtyping approaches to distinguish biological subgroupsof prostate cancer that differ in treatment response,2) identification of new drivers of aggressive prostatecancer; 3) the development of novel therapeutic approachesto treat prostate cancer. He has published manuscripts inleading journals such as the New England Journal ofMedicine, Lancet Oncology, Journal of Clinical Oncology,European Urology, Nature, and Nature Genetics. He hasreceived numerous awards for his research and is theprincipal investigator on multiple grants, from variousfederal and foundation sources.TOM HOPE, MDDr. Thomas Hope is a radiologist and nuclearmedicine physician (an expert in medicalapplications of

CPCC/UCSF PATIENT CONFERENCE . Comprehensive Cancer Center, UCSF June 8, 2019 Cole Hall, UCSF, San Francisco, California CALIFORNIA Prostate Cancer COALITION coverfinal_Layout 1 3/5/2020 10:47 AM Page 1. WELCOME TO THE 2019 CPCC /UCSF . mentioned to UCSF's Dr. Eric Small, who works with that Committee, that CPCC was going to plan a .